Subscribe
2019-11-21-1-
21 November 2019GenericsRory O'Neill

LSPN Europe: new challenges for drug patent owners in Russia

Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
LSPN Europe: understand our business models, say in-house lawyers
26 November 2019   The best lawyers acting for life sciences companies make sure they fully understand their clients’ business models, said in-house counsel at Life Sciences Patent Network 2019.
Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.
Big Pharma
LSPN Europe: English contract law still ‘fit for purpose’ despite Brexit
21 November 2019   English law remains fit for purpose in international contracts in spite of Brexit, heard attendees at Life Sciences Patent Network Europe today, November 21.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
LSPN Europe: understand our business models, say in-house lawyers
26 November 2019   The best lawyers acting for life sciences companies make sure they fully understand their clients’ business models, said in-house counsel at Life Sciences Patent Network 2019.
Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.
Big Pharma
LSPN Europe: English contract law still ‘fit for purpose’ despite Brexit
21 November 2019   English law remains fit for purpose in international contracts in spite of Brexit, heard attendees at Life Sciences Patent Network Europe today, November 21.

More on this story

Big Pharma
LSPN Europe: understand our business models, say in-house lawyers
26 November 2019   The best lawyers acting for life sciences companies make sure they fully understand their clients’ business models, said in-house counsel at Life Sciences Patent Network 2019.
Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.
Big Pharma
LSPN Europe: English contract law still ‘fit for purpose’ despite Brexit
21 November 2019   English law remains fit for purpose in international contracts in spite of Brexit, heard attendees at Life Sciences Patent Network Europe today, November 21.

More features

Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler
WilmerHale gains partner with ‘deep expertise’
Bayer, Orion take on Indian generic over $117bn drug
‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court